Biocardia announces positive consultation with japan pmda on cardiamp cell therapy for ischemic heart failure

Sunnyvale, calif., dec. 04, 2024 (globe newswire) -- biocardia, inc. [nasdaq: bcda], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today the successful completion of a consultation with japan's pharmaceutical and medical device agency (pmda) on the next steps for the submission for registration of its lead therapeutic asset, bcda-01, for the treatment of ischemic heart failure of reduced ejection fraction (hfref).
BCDA Ratings Summary
BCDA Quant Ranking